March 27th 2024
A posthoc analysis of two phase 3 trials identified multiple independent factors associated with better response to vadadustat in patients with anemia.
Semaglutide 1.0 mg (Ozempic) Reduced Kidney Events 24% in FLOW Trial
March 5th 2024Novo Nordisk announced topline data from the FLOW trial indicate semaglutide 1.0 mg (Ozempic) was associated with a 24% reduction in risk of kidney disease-related events among individuals with type 2 diabetes and CKD compared to placebo therapy.
Home-Based Albuminuria Screening Cost-Effective for Preventing Kidney, Cardiovascular Events
February 6th 2024Findings highlight the potential benefits of implementing home-based screening for albuminuria in the general population to reduce the burden of kidney and cardiovascular diseases while maintaining cost-effectiveness.
eGFR Based on Creatinine, Cystatin C May Offer Better CKD Threshold for Older Adults
January 31st 2024Low eGFRcr-cys was more strongly and uniformly associated with adverse outcomes compared to low eGFRcr in an older patient population, highlighting the benefit of including cystatin C in GFR estimation.
Automated AKI Alert Prompts Change of Care, Shows No Impact on Patient Outcomes
January 26th 2024Use of the electronic AKI alert system led to slight improvements in intervention rates and AKI diagnosis, although kidney function and patient-centered outcomes did not differ from patients receiving usual care.
CBT-I, Trazodone Ineffective at Improving Insomnia for Patients on Hemodialysis
January 18th 2024Investigators observed no change in Insomnia Severity Index scores from baseline to weeks 7 and 25 with CBT-1, trazodone, or placebo, suggesting these insomnia treatment options are not effective for patients undergoing hemodialysis.
SGLT-2is Mitigate Risk of Cardiovascular, Kidney Diseases in Patients with Type 2 Diabetes and AKD
January 4th 2024Compared to nonusers, patients with type 2 diabetes and acute kidney disease administered SGLT-2is had a significantly lower risk of mortality, major adverse kidney events, and major adverse cardiovascular events.
Sparsentan Use Could Lower Risk of Kidney Failure, Death in FSGS
November 3rd 2023Although the DUPLEX trial missed its primary endpoint of eGFR slope in patients with FSGS, results point to greater reductions in proteinuria and in risk of kidney failure with sparsentan use relative to irbesartan—making its case for becoming a standard of care for the glomerular disease.
FIDELITY Analysis Details Benefits of Early Albuminuria Reduction in CKD
November 2nd 2023Rajiv Agarwal, MD, MS, provides insight into an analysis from ASN Kidney Week 2023 detailing the effect of early albuminuria reduction on risk of adverse kidney and cardiovascular outcomes in people with T2D and chronic kidney disease.